Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
Denali Therapeutics (DNLI) Stock Price & Analysis
572 Followers
DNLI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.56 - $33.31
Previous Close$19.21
Volume813.11K
Average Volume (3M)1.18M
Market Cap
$2.75B
Enterprise Value$1.76B
Total Cash (Recent Filing)$1.03B
Total Debt (Recent Filing)$44.98M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 06, 2024EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding142,609,036
10 Day Avg. Volume880,476
30 Day Avg. Volume1,180,322
Standard Deviation0.18
R-Squared0.18
Alpha-0.00714
Financial Highlights & Ratios
Price to Book (P/B)2.66
Price to Sales (P/S)8.29
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.34
Enterprise Value/Gross Profit5.32
Enterprise Value/Ebitda6.26
Forecast
1Y Price Target
$42.55Price Target Upside121.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Denali Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentDenali's novel brain shuttle modality shows promise, potentially leading to an expedited development path for their therapies.
Financial StrengthThe company plans to extend its cash runway into 2027, indicating a solid financial position to execute on multiple upcoming inflection points.
Regulatory AdvancementsThe FDA may be open to discussing an accelerated path for the company’s lead asset, which is a significant positive for the total enzyme replacement therapy (ERT) portfolio.
Bears Say
Clinical Trial ResultsPh2 HIMALAYA Trial in ALS Misses Primary Endpoint, casting doubts on the efficacy of the treatment.
Financial ImpactThe analyst's price target is reduced to $40 from $45 due to the dilutive nature of the recent deal, indicating a potential decrease in shareholder value.
Regulatory RiskThe FDA's request to convene an advisory committee for LLY's donanemab could delay its approval timeline, indicating regulatory challenges.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $14.56 and its highest was $33.31 in the past 12 months.
What is Denali Therapeutics’s market cap?
Currently, no data Available
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 73 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on May 07, 2024. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.695 by $0.015.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -$0.67.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 142,609,040 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.695. Following the earnings report the stock price went up 12.166%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Among the largest hedge funds holding Denali Therapeutics’s share is Baker Bros Advisors LP. It holds Denali Therapeutics’s shares valued at 77M.
---
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.55 (121.50% Upside)
$42.55 (121.50% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 899.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.82%
12-Months-Change
Fundamentals
Return on Equity
-11.33%
Trailing 12-Months
Asset Growth
12.19%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
---
DNLI Stock 12 Month Forecast
Average Price Target
$42.55
▲(121.50% Upside)
Technical Analysis
Best Analysts Covering DNLI
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+27.16%
reiterated a buy rating 18 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +27.16% per trade.
---